Reviewing Benitec Biopharma Limited (BNTC)’s and Urovant Sciences Ltd. (NASDAQ:UROV)’s results

Benitec Biopharma Limited (NASDAQ:BNTC) and Urovant Sciences Ltd. (NASDAQ:UROV), both competing one another are Biotechnology companies. We will compare their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Benitec Biopharma Limited N/A 0.00 N/A -0.82 0.00
Urovant Sciences Ltd. N/A 0.00 101.47M -3.21 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of Benitec Biopharma Limited and Urovant Sciences Ltd.


Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Benitec Biopharma Limited 0.00% 0% 0%
Urovant Sciences Ltd. 0.00% 0% 0%

Analyst Ratings

The table given features the ratings and recommendations for Benitec Biopharma Limited and Urovant Sciences Ltd.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Benitec Biopharma Limited 0 0 0 0.00
Urovant Sciences Ltd. 0 0 2 3.00

On the other hand, Urovant Sciences Ltd.’s potential upside is 170.27% and its average target price is $26.

Insider and Institutional Ownership

The shares of both Benitec Biopharma Limited and Urovant Sciences Ltd. are owned by institutional investors at 4.11% and 22.8% respectively. Competitively, 74.9% are Urovant Sciences Ltd.’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Benitec Biopharma Limited 32.73% 44.42% -9.25% -22.06% -33.96% 46%
Urovant Sciences Ltd. 7.69% 46.7% 59.01% 0% 0% 95.45%

For the past year Benitec Biopharma Limited was less bullish than Urovant Sciences Ltd.


Urovant Sciences Ltd. beats Benitec Biopharma Limited on 3 of the 5 factors.

Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. It also offers BB-401 and BB-501 for the treatment of oncology. The company was founded in 1995 and is headquartered in North Sydney, Australia.

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. The company was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.